Infectious disease screening of Namibia blood donations for infectious diseases was contracted to the South African National Blood Service (SANBS) since 2004 and needed to be relocated back to Namibia. A cost analysis conducted showed that by introducing certain strategies, it was cost-effective to implement ID-NAT in Namibia. NAMBTS chose Ultrio Elite assay/Panther System (Gen-Probe and Novartis, USA) for ID-NAT for HIV 1/2 RNA, HBV DNA and HCV RNA and Chemiluminescent immunoassay done on the Architect i2000SR system (Abbott, Delkenheim, Germany) for HIV 1/2 Ag/Ab, anti-HCV, HBsAg and Syphilis. For performance evaluation, the Panther System was compared with the Procleix TIGRIS system-Ultrio Plus assay (Gen-Probe and Novartis, USA) while the Architect system was compared with the Abbott PRISM. The results of this evaluation demonstrated a 100% sensitivity and 100% specificity of the Ultrio Elite assay while the Architect also demonstrated 100% sensitivity and specificity of above 99% for detecting viral markers for HBV, HIV and HCV, and 97% sensitivity and 99Á7% specificity for detecting syphilis. We found both the Procleix Panther and Architect systems to be flexible, robust and effective in screening blood for transfusion in our setting. Donor screening for HIV 1/2, HBV, HCV and syphilis for ID-NAT and serology using the Procleix Panther and Architect systems was successfully relocated from South Africa and implemented in February 2014 in Namibia.
Introduction
The Blood Transfusion Service of Namibia (NAMBTS) was incorporated in 1963 as a non-profit organization and is the only institution licensed by the Government of Namibia to collect, test and distribute blood and blood products to hospitals in the country. NAMBTS operates on a cost recovery basis by billing the recipients of blood whereby the government pays for state patients who consume 83% of the blood and health insurance pays for private patients. NAMBTS collects blood from voluntary non-remunerated blood donors with a whole blood donation rate of 13Á1 per 1000 population, and about 70% of all collections are from repeat donors with a donation frequency of 2Á1 per year.
Each blood donation collected in Namibia is tested for transfusion-transmissible infections (TTI) markers for human immunodeficiency virus type 1 and 2 (HIV 1/2), hepatitis B virus (HBV), hepatitis C virus (HCV) and syphilis. In 2004, TTI testing of Namibia blood donations was temporarily contracted to the South African National Blood Service (SANBS) testing laboratories in Johannesburg, South Africa initially for 1 year while the testing laboratories and systems in Namibia were being refurbished. At SANBS, the donations were screened for p24 ELISA assay (Immunogenetics, Gent, Belgium), anti-HIV 1/2, anti-HCV and hepatitis B surface antigen (HBsAg) by chemiluminescent immunoassay (ChLIA) using the Abbott PRISM; (Abbott, Delkenheim, Germany) as well as for syphilis (TPHA) using the Axis-Shield assay performed on Beckman Coulter PK7300 (Beckman coulter, USA). Donor specimens were flown to South Africa at the end of each day and delivered before midnight and tested overnight for the results to be emailed by twelve noon the next day. The results were emailed in a text format compatible with our laboratory information system (LIS) and would be imported and transferred to the LIS allowing non-reactive donations to be marked for release.
In order to reduce the risk of transfusion-related infection, more sensitive NAT could be used to directly detect viral genomes which had already been implemented in the US, Canada, Japan, Australia and a number of European countries, and this represented an important advance in blood safety control [1] . In response to the escalating threat of the HIV/AIDS epidemic to the safety of the blood in South Africa, SANBS introduced individual donation nucleic acid test (ID-NAT) screening for HBV, HCV and HIV-1 in their two blood testing laboratories in October 2005 [2] . Studies at that time showed that, in a high-prevalence setting, simultaneous screening of donations with ID-NAT and serology assays would provide the highest level of safety and would be the most practical approach [2] , interdicting transfusion-transmissible infectious diseases which are likely to be transmitted by blood from donors in the seronegative window period of viral infection. SANBS offered to screen donors from Namibia for ID-NAT as well; however, this would increase the cost of screening by 60%. Considering the hyperendemicity of HIV and HBV in Namibia at the time which was 16Á8% for HIV and >8% for HBV [3] [4], NAMBTS decided to keep TTI testing at SANBS to benefit from the ID-NAT screening. Like many small economies, adding NAT to blood screening was not affordable for Namibia, but necessary for established blood safety measures and had to be adopted at all cost [5, 6] . Relocating blood screening with ID-NAT to Namibia at that time was not cost-effective for a small blood service such as Namibia which was collecting a volume of 18 000 blood donations annually.
After the launch of the Procleix Panther system in 2012 which is compact yet delivers high-quality, fully automated and integrated blood screening to laboratories of all sizes from community blood centres to consolidated testing facilities around the world [7] , NAMBTS investigated the possibility of relocating TTI screening including ID-NAT to NAMBTS laboratories in Windhoek, by that time blood collections had increased to 24 000 per annum and were projected to increase by 8% every year. A cost-effective analysis showed that relocating TTI screening both serology and ID-NAT would cost 23% more. Despite the increase in cost, NAMBTS decided to relocate blood donor screening for HIV1/2, HBV, HCV and syphilis to NAMBTS laboratories in Windhoek. To help subsidize the cost of blood screening, surplus plasma would be exported to Natal Bio-products Institute (NBI); the fractionator, in South Africa to be fractionated, the revenue generated would contribute 17% to total cost of TTI testing and the deficit was going to be addressed through increases in product charges and this was agreed by all stakeholders of our National Blood Programme.
Selection of the TTI screening systems
Suppliers of TTI blood screening systems were invited to submit quotations for ID-NAT and serology and make presentations of their systems. For ID-NAT multiplex blood screening systems for HIV 1/2, HBV and HCV, the Procleix Ultrio Elite assay on the Procleix Panther system (Gen-Probe, San Diego, CA USA) and the Cobas s201 Taqscreen MPX (Roche Molecular Systems, Pleasanton, CA, USA) were compared while for serology chemiluminescent (ChLIA) immunoassay for HIV 1/2, HBsAg, anti-HCV and antibodies to Treponema pallidum, the Abbott Architect i2000SR (Abbott, Delkenheim, Germany) and Roche's Cobas e601 were compared. Assay systems were compared based on cost and sustainability, assay type and technology, sensitivity and specificity, ease of use and the size of the instrument versus available laboratory space. The sensitivity of the Ultrio Elite assay which is run on the Panther blood screening system is comparable to the Ultrio Plus assay apart from the addition of oligonucleotides for human immunodeficiency virus type 2 (HIV-2) detection [8] and the Ultrio Plus and the Cobas s201 Taqscreen MPX are reported to be of equal sensitivity [9] [10] [11] [12] [13] [14] , we therefore assumed no significant differences on the performance of the Ultrio Elite and the Cobas s201 Taqscreen MPX. The cost of the Panther system was 0Á2% higher than that of the Cobas s201 Taqscreen MPX; however, the size of the Cobas s201 Taqscreen MPX was too high to fit into our laboratory space compared to the Panther instruments as we needed two instruments to include a back-up. After the assessment of these two NAT platforms, we decided to adopt the Ultrio Elite assay run on the Panther system. On serology screening, the Abbott Architect i2000SR and Cobas e601 were assessed for testing HIV 1/2 Ag/Ab, HBsAg, anti-HCV and antibodies to T. pallidum. Unfortunately, the Cobas e601 did not have an assay for syphilis on its menu at that time, and adding another system for screening syphilis would cost significantly more compared to the Architect i2000SR, and therefore, we decided to adopt the Architect i2000SR. By November 2013, two Procleix Panther systems and Architect i2000SR systems were placed in our testing laboratories in Windhoek and the performance evaluation of these systems was commenced.
Evaluation methods
The evaluation of specificity and sensitivity comprised parallel testing of samples at NAMBTS and comparing with results obtained from routine testing samples from the same donors performed by SANBS. The Procleix Panther system (Ultrio Elite assay), (Gen-Probe, San Diego, CA USA) was compared against the Procleix Tigris system (Ultrio Plus), (Gen-Probe, San Diego, CA, USA) as a 'gold standard' or reference assay method. The manufacturer and some studies claim that they have comparable sensitivity levels apart from the addition of oligonucleotides for human immunodeficiency virus type 2 (HIV-2) detection on the Ultrio Elite assay [8] . For virology markers, anti-HIV 1/2, HBsAg and anti-HCV, our Architect i2000SR system (Abbott Diagnostic Division, Abbott Park, USA) was compared against the Abbott PRISM (Abbott, Delkenheim, Germany) as a reference system, both systems use the chemiluminescent (ChLIA) immunoassay, while for syphilis, the Architect (ChLIA syphilis TP) was compared with a TPHA assay performed on the Olympus PK7300 (Olympus America, Center Valley, USA) as a reference system.
Evaluation of specificity
A total of 2827 blood donors who donated between 1 and 30 December in Namibia were screened during the evaluation period. Two sets of specimens (2 9 10 ml ethylenediaminetetraacetate (EDTA) for ID-NAT and 2 9 6 ml clotted for serology) were collected from each donor who participated. The first set of specimens (one EDTA and one clotted) were screened at NAMBTS by ID-NAT for HIV 1/2 RNA, HBV DNA and HCV RNA using the Ultrio Elite assay on the Panther system and for HIV Ag/Ab, HBsAg, anti-HCV and T. pallidum antibodies, using a ChLIA on the Architect systems. While the second set was tested at SANBS by ID-NAT (HIV 1 RNA, HBV DNA and HCV RNA) using Ultrio Plus assay on the Procleix TIGRIS system and for anti-HIV-1/2, anti-HCV and HBsAg using a ChLIA on the PRISM. Syphilis was screened using a TPHA assay performed on the Olympus PK7300. Samples with an initial reactive (IR) result for ID-NAT were retested in duplicate with the Ultrio Plus and Ultrio elite assays as well as with the discriminatory probe assays for HIV-1 (HIV 1/2 with Ultrio elite), HCV and HBV on both systems. The discriminatory assay is identical to the Ultrio multiplex assay except that the probe is specific for HIV-1 RNA (HIV 1/2 on the Panther system), HCV RNA or HBV DNA. All samples with an IR result on the PRISM and Architect were also retested in duplicate. If one of the duplicate repeat tests was seropositive with a nonreactive ID-NAT, then different supplemental test protocols were followed. For HIV, an immunoblot assay (Immunocomb HIV CombFirm II, Orgenics Ltd., Yavne, Israel) was performed for HCV (Monolisa anti-HCV Plus, Bio-Rad), and a neutralization test was performed for HBsAg (Elecsys, Roche Diagnostics, Pleasanton, CA). All supplementary testing was done at the SANBS Johannesburg laboratory. ChLIA repeat reactive results for syphilis were confirmed using manual TPHA and VDRL test methods. The results were interpreted according to the algorithms in Tables 1 and 2 .
Blood products from these donations were released after both NAMBTS and SANBS results were negative. All specimens that were reactive with ID-NAT (Ultrio Elite assay) were discriminated using the discriminatory NAT assay to identify the virus. Test results from SANBS were compared with those obtained from the new systems at NAMBTS.
Evaluation of sensitivity
Only 28 specimens of the 2827 (0Á1%) were reactive in various assays (six HIV, 14 HBV, five HCV and three Syphilis), and these were not enough to assess sensitivity of the test systems. Therefore, an additional 163 samples were categorized as follows, and 30 TPHA reactive samples were obtained from SANBS; Plus) non-reactive, anti-HCV repeat reactive confirmed by a Monolisa anti-HCV Plus (4) 30 TPHA reactive samples. Table 3 shows the number of reactive samples per category received from SANBS.
The samples were received from SANBS already categorized in the categories shown in Table 3 , and we did not receive data on the viral loads of these samples. Samples reactive for HIV, HBV and HCV were tested by ID-NAT with Ultrio Elite assay and with the chemiluminescent assay for the markers of the virus for which they were reactive while syphilis reactive samples were tested using the ChLIA with the Architect. Samples categorized as 'Infected' were expected to be reactive in the first screen; however, if any yields (NAT or serology) were non-reactive in the first screen, they were replicated at least six times and were considered reactive if more than 50% of the replicates (including discriminatory for NAT) were reactive. Samples that were ID-NAT reactive by Ultrio Plus were also discriminatory reactive, and serology yields were confirmed by supplementary testing according to SANBS algorithm before they were dispatched to us. The results from NAMBTS systems were interpreted and categorized as infected, NAT yield and serology yield, that is, in the same way as in the Tables 1 and 2 and then compared with SANBS results.
Reproducibility was also assessed from the results of the samples from SANBS that were tested in replicates of six or more, these were mainly NAT and serology yields which are expected to have very low viral loads.
Results
Of the 2827 donors from Namibia that were screened, 38 (1Á3%) of them were repeat reactive for the markers they found to be reactive. There were three initial reactive samples in syphilis ChLIA due to sample contamination as these were non-repeat reactive, and therefore, the donations were considered to be negative. From the samples that were repeat reactive, 14 (0Á5%) donations were reactive for HBV with both ID-NAT and HBsAg, while six (0Á21%) were reactive in HIV ID-NAT with four of these being reactive with HIV Ag/Ab, two of the HIV reactive donations were HIV NAT yields (non-reactive with the HIV Ag/Ab). Five (0Á18%) donations were anti-HCV reactive with a non-reactive NAT and were also non-reactive in supplementary testing. While three (0Á11%) donations were considered reactive for syphilis, although 10 more were also reactive with syphilis ChLIA on Architect only, the supplementary testing at NAMBTS using TPHA and VDRL tests of these produced non-reactive results and was considered false reactive donations according to our algorithms in Table 2 . Table 4 summarises these results. There was 100% concordance on the results of viral markers of HIV 1/2, HBV and HCV between NAMBTS and SANBS systems although both the PRISM and Architect tested positive in five of the donations, these results were negative in supplementary testing and therefore considered to be biological false positives. There was 99Á6% (2817/2827) concordance between the Architect and Olympus PK7300 in detecting T. pallidum antibodies in these donations.
Results of positive panels from SANBS are shown in Table 5 A total of 65 HBV positive panels were analysed using the Panther system (Ultrio Elite assay) for ID-NAT and Architect (ChLIA) for HBsAg. A total of 30 syphilis-positive panels from SANBS were analysed using the Architect systems (ChLIA Syphilis TP assay) for anti-T. pallidum antibodies, and 29 of 30 (96Á7%) were detected by the Architect (Table 6) .
In order to calculate sensitivity and specificity. Total samples tested for HBV and HIV are 2892 while those tested for HCV were 2860 and 2857 were tested for syphilis. 
NR NR n/a n/a Non-infected NR n/a n/a n/a n/a Non-infected ChLIA, chemiluminescent assay; TPHA, Treponema pallidum haemaglunination assay; VDRL, Venereal Disease Research Laboratory. n/a n/a n/a 3 VDRL 13 n/a n/a n/a 0 SANBS Procleix Tigris 2827 6 14 0 n/a Architect PRISM 2827 4 14 5 n/a PK7300 2827 n/a n/a n/a 3
To ensure the additional sensitivity in detecting the serology yields was not laboratory contamination, we tested each of the seven HBsAg yields and one anti-HIV yield samples in six replicates and at least five of the six replicates of each sample were reactive indicating more than 80% reproducibility levels at very low viral loads.
Equipment failures during evaluation
No invalid runs were encountered; however, 172 (6%) of ID-NAT tests were invalid and had to be repeated. Approximately 80% of these failures were hardware related (an output queue error due to deflector problems) and this problem was eventually resolved when the waste cover was modified by the engineers, while 20% of the failures were sample integrity related as all the samples from SANBS were previously frozen and we experienced 'Magnetic Wash' errors from a few of these samples. There were no operator-related errors/failures.
Analysis of sensitivity and specificity
The results shown in Tables 5 and 6 were used to calculate sensitivity and specificity levels of both the Panther and Architect systems as shown in Tables 7 and 8 . The Panther system has shown 100% sensitivity in detecting all the markers while the Architect system also showed 100% in detecting all the markers except syphilis which had a sensitivity of 97%. Specificity of the Panther was 100% on all the markers while the Architect demonstrated 100% specificity on all the markers except anti-HCV and syphilis which had 99Á8% and 99Á7%, respectively.
Discussion
We tested a month's worth of donor samples for specificity and 193 known positive samples for sensitivity. Ultrio Elite and Architect detected all samples that were expected to be reactive, demonstrating 100% concordance with the reference test systems.
All 25 SANBS HBV yield samples were detected by the Ultrio Elite assay, one-fifth were in addition had detectable HBsAg in the Architect assay. This shows improved sensitivity of the Architect systems when compared to Prism system in detecting HBsAg in low surface antigens levels. The remaining 80% were confirmed NAT yields, that is ID-NAT reactive and HBsAg non-reactive, with one of these being an un-typed NAT yield, that is Ultrio Elite-reactive, dHBV-non-reactive and HbsAg-reactive possibly because HBV DNA levels in this sample may be below the assay's limit of detection. All 25 SANBS HIV yield samples were detected by the Ultrio Elite assay and in addition, about a third of the samples were reactive on the Architect system, this demonstrates improved sensitivity of 4th generation chemiluminescence assay on the Architect compared to the 3rd generation anti-HIV test on the Prism while the remainder were confirmed NAT yields, that is ID-NAT reactive and HIV Ag/Ab non-reactive. All the HCV NAT yield samples were confirmed as HCV NAT yields using our NAT and serology assays. The overall sensitivity of the Panther system on detecting NAT yield cases of all the three viruses was 100% and comparable to that of the Tigris systems as all samples categorized as NAT yields were reactive in the ID-NAT assays. Our Architect system proved to be more sensitive than the Prism in detecting both HBsAg and HIV Ag/Ab markers in these NAT yield samples as five samples which were not reactive for HBsAg and nine samples which were not reactive for anti-HIV-1 on the Prism were reactive for the respective markers on the Architect. Serology yield samples have very low viral DNA/RNA below the detection level of the NAT test system in use but with detectable antigens and/or antibodies, and in some cases especially with HCV, there is no RNA as the donor would have successfully cleared the virus. All 15 SANBS HBsAg yield samples were detected by the Architect and in addition about half of them were reactive with the Panther as well; these were non-reactive on the Tigris system but confirmed reactive in replicates on the Panther system. On personal communication with Mr Ravi Reddy and Mrs Marion Vermeulen from SANBS, they indicated that 13 of these 15 HBsAg yields were in fact screened using the Ultrio assay before SANBS upgraded to Ultrio Plus assay [15] . Ultrio assay has low sensitivity on detecting HBV DNA and the assay was improved to Ultrio Plus after the addition of the Target Enhancer Reagent (TER) which improved viral rapture and capturing of HBV DNA before amplification. A study by Vermeulen and colleagues also suggested that there may be a subpopulation of HBV strains in South Africa donors that is poorly detected by the Ultrio assay and will be picked up with more than 10-fold higher sensitivity by the addition of the TER in the Ultrio Plus assay [9] . We then concluded that these results were to be expected as Ultrio Elite assay uses the TER reagent as well and is therefore more sensitive than Ultrio assay in detecting HBV DNA.
All 15 SANBS anti-HIV yield samples were detected by the Architect, and in addition one of these samples was reactive with the Panther system as well. This could mean that this sample had HIV-2 virus RNA and not HIV-1 virus RNA as the Ultrio Plus assay is designed to detect HIV-1 RNA only while Ultrio Elite is designed to detect both HIV-1 and HIV-2 RNA [13], we could not confirm this though. Although infection with HIV-2 occurs mainly in West Africa, the incidence of HIV-2 infections may increase in the rest of the world including Southern Africa due to increasing immigration from Western African countries where HIV-2 is endemic [16] . Grabarczyk and colleagues also concluded that the Ultrio Elite assay that is run on the Panther blood screening system is comparable to the Ultrio Plus assay apart from the addition of oligonucleotides for human immunodeficiency virus type 2 (HIV-2) detection [8] . If this sample has HIV-1, it is logical to assume that the Ultrio Elite assay has improved sensitivity in detecting HIV-1 RNA as compared to the Ultrio Plus assay; however, the sample size is too small for us to reach this conclusion. However, as this sample is expected to have low levels of RNA, this scenario could be reflecting the impact of Poisson sampling rather that Ultrio Elite being more sensitive than Ultrio Plus. The literature from the manufacturer claims that both Ultrio Plus and Ultrio Elite assays have equal sensitivity levels. All the anti-HCV yield samples were confirmed as anti-HCV yields after testing with Panther and Architect systems.
In this evaluation study, the overall sensitivity and specificity of the Panther system (Ultrio Elite assay) were found to be 100%, as shown in Table 7 . On the other hand, the sensitivity of the Architect systems was 100% for all markers and 97% for syphilis while the specificity for all the markers was 100% except anti-HCV and syphilis which was 99Á8% and 99Á7% respectively as shown in Table 8 . The evaluation demonstrated that both the Panther and the Architect systems have acceptable sensitivity and specificity levels. The evaluation also confirmed the claims of the manufacturer that Ultrio Elite assay is as sensitive as the Ultrio Plus in detecting HIV-1 RNA and HCV RNA but more sensitive than the Ultrio assay in detecting HBV DNA. We could also demonstrate that our test systems for detecting syphilis have acceptable sensitivity and specificity levels. We found both the Panther and Architect systems to be flexible, robust and effective in screening blood for transfusion in our setting. Donor screening for HIV 1/2, HBV, HCV and syphilis for ID-NAT and serology using the Panther and Architect systems was successfully relocated from South Africa and implemented in Namibia.
